Sexually transmitted diseases最新文献

{"title":"Infection Positivity Among Sexual Contacts to Chlamydia and Gonorrhea, STI Surveillance Network, 2021-2023.","authors":"Eloisa Llata, Brandi Danforth, Jennifer Tang, Lenore Asbel, Christopher Ried, Madison Blust, Anna Berzkalns, Christina Schumacher","doi":"10.1097/OLQ.0000000000002210","DOIUrl":"10.1097/OLQ.0000000000002210","url":null,"abstract":"<p><strong>Background: </strong>Patients reporting sexual contact with a person(s) with chlamydia (CT) and/or gonorrhea (NG) are at increased risk of acquiring these sexually transmitted infections (STIs). Presumptive antimicrobial therapy is recommended for sexual contacts, but concerns have been raised about unnecessary antibiotic use.</p><p><strong>Methods: </strong>We reviewed visits of patients who reported sexual contact to a partner with CT or NG (\"contacts\") from January 2021 to October 2023 in 10 STI clinics. We calculated CT and NG positivity, stratified by 3 patient groups (women, men who have sex with men, and men who have sex with women only [MSW]) and symptomatic status.</p><p><strong>Results: </strong>Overall, 11,072 (6.8%) CT and/or NG contacts were identified (7660 [4.7%] CT contacts and 4988 [3.1%] NG contacts). Chlamydia positivity among CT contacts was 35%; NG positivity among NG contacts was 31%. Chlamydia positivity did not differ by symptomatic status across patient groups. Gonorrhea positivity was higher for symptomatic versus asymptomatic men who have sex with men (34% [95% confidence interval {CI}, 31%-37%] vs. 28% [95% CI, 26%-30%]) and MSW (37% [95% CI, 33%-41%] vs. 23% [95% CI, 20%-27%]), but not in women (38% [95% CI, 33%-43%] vs. 37% [95% CI, 32%-42%]).</p><p><strong>Conclusions: </strong>Substantial CT/NG positivity among sexual contacts to CT or NG was observed. Among CT contacts, CT infection was most often detected in MSW; among NG contacts, NG infection was most often detected in women. However, ~60% did not have either CT or NG. The use of point-of-care tests in this population may optimize antimicrobial use while prioritizing individual clinical care.</p>","PeriodicalId":21837,"journal":{"name":"Sexually transmitted diseases","volume":" ","pages":"654-658"},"PeriodicalIF":1.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and Sociodemographic Factors Associated With Ocular Mpox in California, May 2022 to September 2023.","authors":"Wyatt Hanft, Kayla Saadeh, Robert E Snyder, Jessica Watson, Eric C Tang, Eric Chapman, Marisa Ramos, Kelly A Johnson","doi":"10.1097/OLQ.0000000000002195","DOIUrl":"10.1097/OLQ.0000000000002195","url":null,"abstract":"<p><strong>Background: </strong>Inoculation of the eye with monkeypox virus can cause vision-threatening disease necessitating hospitalization and urgent treatment. Ocular mpox is poorly understood, including who is most affected.</p><p><strong>Methods: </strong>We performed a cross-sectional study comparing ocular and non-ocular mpox cases reported to the California Department of Public Health from May 1, 2022, to September 30, 2023. χ2 and t tests were used to compare between-group sociodemographic characteristics, HIV status, and vaccine status. Bivariate and multivariate logistic regressions adjusting for HIV and race/ethnicity were used to calculate odds ratios and 95% confidence intervals for the association between JYNNEOS vaccination and ocular mpox.</p><p><strong>Results: </strong>Of 5878 mpox infections, 2403 (40.9%) had complete ocular symptom reporting and were included in this analysis. Of these, 260 (10.8%) were ocular cases. Among the 2403 included cases, most were cisgender men (94.6%) and reported male-to-male sexual contact (72.0%). The proportion of non-ocular versus ocular mpox cases differed significantly by race/ethnicity and HIV status ( P < 0.05), with more ocular cases being Hispanic/Latinx (50.8% vs. 41.8%), Black (14.2% vs. 8.9%), and with HIV (50.8% vs. 40.4%). After adjusting for race/ethnicity and HIV status, people with ≥1 dose of JYNNEOS had approximately half the odds of having ocular symptoms compared with people who were unvaccinated (adjusted odds ratio, 0.52; 95% confidence interval, 0.24-0.97).</p><p><strong>Conclusions: </strong>A higher proportion of Black, Latinx, or people living with HIV had ocular mpox symptoms, suggesting that these groups may benefit from focused interventions to prevent infection and this complication. JYNNEOS before mpox exposure may protect against ocular complications, stressing the importance of vaccination to prevent severe sequelae, especially for vulnerable populations.</p>","PeriodicalId":21837,"journal":{"name":"Sexually transmitted diseases","volume":" ","pages":"684-689"},"PeriodicalIF":1.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Survey Study of Concerns and Attitudes Towards Doxycycline Post-Exposure Prophylaxis (DoxyPEP) Among Bathhouse-Affiliated Individuals in the U.S. and Canada.","authors":"Michael Wasz, Aniruddha Hazra, Laura Rusie, Geoffroy Liegeon, Nirmalpal Sachdev, Irina Tabidze, Supriya D Mehta","doi":"10.1097/OLQ.0000000000002255","DOIUrl":"https://doi.org/10.1097/OLQ.0000000000002255","url":null,"abstract":"<p><strong>Abstract: </strong>This study assesses doxycycline post-exposure prophylaxis (doxyPEP) awareness, perceptions, and concerns among bathhouse-affiliated individuals. Antimicrobial resistance, adverse effects, and accessibility were primary concerns. Partnerships with bathhouses present opportunities to address these barriers through targeted education, enhancing acceptance and promoting doxyPEP's effectiveness in preventing sexually transmitted bacterial infections.</p>","PeriodicalId":21837,"journal":{"name":"Sexually transmitted diseases","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145303594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in chlamydia prescribing practices after changes to national treatment guidelines in the United States, 2016-2023.","authors":"Christine M Khosropour, Guoyu Tao, Lindley A Barbee","doi":"10.1097/OLQ.0000000000002251","DOIUrl":"https://doi.org/10.1097/OLQ.0000000000002251","url":null,"abstract":"<p><strong>Background: </strong>In 2021 the US Centers for Disease Control and Prevention revised Chlamydia trachomatis (CT) treatment guidelines to recommend only doxycycline as first line-therapy, instead of recommending either azithromycin or doxycycline. The extent to which this recommended change has been translated into practice is unknown.</p><p><strong>Methods: </strong>We used 2016-2023 MarketScan data (national convenience sample of insurance claims from individuals with employer-sponsored insurance and Medicaid beneficiaries from 8-12 states) to identify encounters of CT diagnoses for individuals aged 15-60 years old who were treated with doxycycline or azithromycin within 14 days after diagnosis. We examined trends in doxycycline treatment before and after the 2021 change to the treatment guidelines. We compared receipt of doxycycline in 2022 by characteristics and facility/provider type.</p><p><strong>Results: </strong>We included 154,200 encounters. Between 2016-2020, the percentage prescribed doxycycline remained stable at 17%. In 2021 and 2022, the percentage prescribed doxycycline increased to 37.6% and 57.1%, respectively. In 2022, women were significantly less likely to receive doxycycline compared to men (commercial: 55.3% vs. 76.5%; Medicaid: 48.2% vs. 71.5%), and people under age 25 were significantly less likely to receive doxycycline compared to those >25 (commercial: 61.0% vs. 67.4%; Medicaid: 50.8% vs. 57.4%). People treated in an emergency department were significantly more likely to receive doxycycline compared to other clinicians/facility types.</p><p><strong>Conclusions: </strong>There has been rapid uptake of the new CT treatment guidelines; however, those at risk of acquiring CT (women and those aged <25 years) are the least likely to receive recommended treatment.</p>","PeriodicalId":21837,"journal":{"name":"Sexually transmitted diseases","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145287022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neighborhood Social Vulnerability and Access to Expedited Partner Therapy Prescriptions: A Secret Shopper Audit Survey.","authors":"Rachel E Solnick, Carmen C Vargas- Torres, Alexa Guastello, Marissa Seldes, Kelsey Simpson, Patricia Mae Martinez, Michael Grant, Ethan Cowan","doi":"10.1097/OLQ.0000000000002252","DOIUrl":"https://doi.org/10.1097/OLQ.0000000000002252","url":null,"abstract":"<p><strong>Background: </strong>Sexually transmitted infections (STIs) disproportionately affect socially vulnerable populations. Expedited Partner Therapy (EPT) reduces reinfection rates by treating partners without requiring a medical visit yet remains underutilized in the electronic prescription era. Studies show low pharmacist awareness of EPT, with limited research on its real-world availability in pharmacies or variability by Social Vulnerability Index (SVI) factors. This study assessed pharmacist awareness and willingness to fill hypothetical nameless electronic EPT prescriptions in New York City (NYC) pharmacies and examined variations by SVI.</p><p><strong>Methods: </strong>A cross-sectional audit survey of 335 NYC pharmacies employed a telephone-based secret shopper approach. Pharmacist awareness of EPT, willingness to fill, and insurance acceptance were evaluated. Multivariable logistic regression examined associations with SVI, adjusting for pharmacy type, location, and local chlamydia rates.</p><p><strong>Results: </strong>Of surveyed pharmacies, 40% were aware of EPT, with significantly lower awareness in non-chain pharmacies than national chains (34% vs. 54%, p = 0.02). Only 28% of pharmacists stated they would be willing to fill nameless prescriptions. Most prescriptions (34%) would be filled under the index patient's name, and 86% would accept insurance. Common reasons for refusal included unfamiliarity with EPT (62%) and misconceptions about legal name requirements (28%). Awareness was higher in pharmacies located in the highest SVI quartile (OR 3.7; 95% CI 1.4-10.8), but willingness to fill did not vary by SVI (p = 0.35).</p><p><strong>Conclusions: </strong>Despite greater EPT awareness in socioeconomically vulnerable areas, pharmacist willingness to fill nameless EPT prescriptions remains limited across areas. Efforts to educate pharmacists and standardize e-prescribing processes are needed to expand EPT access and reduce STI disparities.</p>","PeriodicalId":21837,"journal":{"name":"Sexually transmitted diseases","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145287043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Critical Considerations on the Proposed In Vitro Secnidazole Susceptibility Breakpoint for Trichomonas vaginalis.","authors":"Amr Kassem, Manisha Timalsena, Siffat Ullah, Hussain Ramzan","doi":"10.1097/OLQ.0000000000002253","DOIUrl":"https://doi.org/10.1097/OLQ.0000000000002253","url":null,"abstract":"<p><strong>Abstract: </strong>This correspondence calls into question the research by Graves et al. that determines an in vitro minimal lethal concentration (MLC) of 12.5 μg/ml for secnidazole (SEC) as linked to clinical resolution in Trichomonas vaginalis [1]. Recognizing the significance of establishing SEC susceptibility thresholds with increasing metronidazole (MTZ) resistance, we highlight several critical limitations: (1) No pharmacokinetic-pharmacodynamic (PK-PD) validation correlating the MLC with attainable drug concentrations in genital tissue; (2) Omission of isolates from males even with their roles in morbidity/reservoirs; (3) Neglect of the impact of vaginal microbiota on drug-parasite dynamics; (4) Absence of analysis on molecular resistance mechanisms; and (5) Possible selection bias due to the low representation of clinical SEC failures (n = 5) and MTZ-resistant isolates (n = 1).</p>","PeriodicalId":21837,"journal":{"name":"Sexually transmitted diseases","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145287054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EFFECTIVENESS OF INCENTIVES ON STI TESTING UPTAKE: A TRIAL AMONG ABORIGINAL AND TORRES STRAIT ISLANDER YOUNG PEOPLE IN REMOTE CENTRAL AUSTRALIA (2015-2020).","authors":"Kate Whitford, Bronwyn Silver, Handan Wand, Stephen Bell, Skye McGregor, Basil Donovan, Christopher Fairley, Rebecca Guy, Nathan Ryder, John Boffa, James Ward, John Kaldor","doi":"10.1097/OLQ.0000000000002254","DOIUrl":"https://doi.org/10.1097/OLQ.0000000000002254","url":null,"abstract":"<p><strong>Background: </strong>Bacterial sexually transmissible infections (STIs) cause a substantial disease burden worldwide, and disproportionately impact young people. In Australia, Aboriginal and Torres Strait Islander people are a priority population in STI testing guidelines.</p><p><strong>Methods: </strong>The More Options for STI Testing (MOST) trial evaluated whether providing an incentive impacted STI testing rates in select central Australian communities. Aboriginal and Torres Strait Islander people aged 16 to 29 years were eligible for a A$30 phone voucher if they had an STI test at a participating Aboriginal community-controlled primary health care clinic. An interrupted time series analysis examined monthly STI test counts for chlamydia, gonorrhoea or syphilis from 2015 to 2020, to determine whether testing increased during the incentives phase (2018-2020).</p><p><strong>Results: </strong>There were a total of 10,457 visits to the clinic in which an STI test was conducted, 5,110 of which were during the incentives period. A total of 1,526 incentives were provided to eligible clients. The baseline and incentives periods were each divided into two phases to account for new clinic openings and the COVID-19 pandemic. Among men, average monthly visits for an STI test were 32.6 (baseline phase 1), 44.1 (baseline phase 2), 50.8 (incentives phase), and 35.4 (incentives/COVID-19 phase). Women had 93.5, 111.3, 118.8 and 113.4 visits respectively. No significant change in STI testing was observed during the incentives phase. The proportion of visits for an STI test where an incentive was paid (coverage) varied by month, from 36% to 76% of consultations.</p><p><strong>Conclusions: </strong>The limited impact of incentives could be explained by low coverage, or that the incentive was not motivating enough to overcome STI testing barriers. Future studies should investigate alternative methods of increasing STI testing in remote central Australia, including through primary care clinics.</p>","PeriodicalId":21837,"journal":{"name":"Sexually transmitted diseases","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145287071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics associated with breakthrough congenital syphilis in Florida and Arizona, 2018-2022.","authors":"Joshua Lassen, Breanne Anderson, Maegan Matter, Felicia M T Lewis, Nicole L Davis, James Matthias","doi":"10.1097/OLQ.0000000000002249","DOIUrl":"https://doi.org/10.1097/OLQ.0000000000002249","url":null,"abstract":"<p><strong>Abstract: </strong>Congenital syphilis (CS) can occur despite timely identification and adequate treatment of maternal syphilis (breakthrough CS). We examined associations between maternal characteristics and prevalence of breakthrough CS. Having primary/secondary syphilis, a higher maximum non-treponemal titer, and treatment initiation closer to delivery were associated with higher prevalence of breakthrough CS.</p>","PeriodicalId":21837,"journal":{"name":"Sexually transmitted diseases","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pilot study of social media promotion of home-based self-testing for syphilis.","authors":"Deena Afana, Kelsey Bass, Chrysovalantis Stafylis, Jeffrey D Klausner","doi":"10.1097/OLQ.0000000000002250","DOIUrl":"https://doi.org/10.1097/OLQ.0000000000002250","url":null,"abstract":"<p><strong>Abstract: </strong>We promoted home-based syphilis self-testing via social media to persons with factors linked to increased syphilis risk in Los Angeles County and San Bernardino. Users found the First to Know Syphilis Test easy and were likely to recommend it, indicating strong interest in self-testing and potential to enhance syphilis prevention.</p>","PeriodicalId":21837,"journal":{"name":"Sexually transmitted diseases","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human Papillomavirus Vaccine Effectiveness by Age, Age at Vaccination, and Timing of Vaccination Relative to Age at First Sex Among Men Who Have Sex With Men-Seattle, Washington, 2018 to 2020.","authors":"Stephanie A Buchbinder, John Lin, Lauri E Markowitz, James P Hughes, Troy D Querec, Elizabeth R Unger, Damilola Dada, Alfred Iqbal, Matthew R Golden, Elissa Meites, Carla L DeSisto, Rachel L Winer","doi":"10.1097/OLQ.0000000000002192","DOIUrl":"10.1097/OLQ.0000000000002192","url":null,"abstract":"<p><strong>Background: </strong>We evaluated human papillomavirus (HPV) vaccine effectiveness (VE) against prevalent anal HPV among men who have sex with men (MSM) by age, age at vaccination, and age at vaccination relative to age at first sex.</p><p><strong>Methods: </strong>Residual anal specimens from 1092 MSM aged 18 to 45 years attending a Seattle, Washington, sexual health clinic in 2018 to 2020 were tested for 28 HPV types. Demographic, clinical, sexual behavioral, and HPV vaccination data were extracted from clinic and electronic medical records. We calculated adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs) for associations between vaccination (≥1 dose of any HPV vaccine) and quadrivalent HPV vaccine (4vHPV)-type infection, by age group (18-26, 27-35, 36-45 years), vaccination age (among age groups 18-26, 27-35 years), and vaccination age relative to first sex (among those 18-26 years). Analyses were adjusted for race and ethnicity, preexposure prophylaxis use for HIV prevention, and lifetime number of sex partners. Vaccine effectiveness was calculated as (1 - aPR) × 100.</p><p><strong>Results: </strong>Among persons aged 18 to 26 years, 4vHPV-type HPV prevalence was lower among those vaccinated before first sex (aPR, 0.12 [95% CI, 0.02-0.87]; VE, 88%) or at <18 years of age (aPR, 0.22 [95% CI, 0.07-0.68]; VE, 78%) versus unvaccinated, but no VE was observed in those vaccinated at 18 to 26 years of age. Among persons aged 27 to 35 years, 4vHPV-type HPV prevalence was lower among those vaccinated at 18 to 26 years of age versus unvaccinated (aPR, 0.56 [95% CI, 0.36-0.87]; VE, 44%). No VE was observed in persons aged 27 to 35 or 36 to 45 years who were vaccinated at >26 years of age.</p><p><strong>Conclusions: </strong>Results highlight the importance of routine HPV vaccination in adolescence and support efforts to increase catch-up vaccination among MSM.</p>","PeriodicalId":21837,"journal":{"name":"Sexually transmitted diseases","volume":" ","pages":"631-640"},"PeriodicalIF":1.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12258699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}